Signal from the log
Moonwalk Biosciences
70 M$ · Series B · United States · Biotech
Moonwalk Biosciences conçoit des ARN interférents adressés au tissu adipeux, pour agir sur des voies de l'homéostasie énergétique qui ne passent pas par les incrétines. Son candidat MW101 vise l'obésité et les maladies cardiométaboliques, avec une entrée en clinique annoncée pour la fin 2027.
Verified
Announced on , logged by the watch of 8 September 2026.
- Operation
- Funding round
- Announced amount
- 70 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Alpha Wave , YK Bioventures , with Eli Lilly and Company , Gaorong Ventures
Provenance
Logged on 8 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.